Marburg virus VP40 antagonizes interferon signaling in a species-specific manner
Marburgviruses are zoonotic pathogens that cause lethal hemorrhagic fever in humans and nonhuman primates. However, they do not cause lethal disease in immunocompetent mice unless they are adapted to this species. The adaptation process can therefore provide insight into the specific virus-host inte...
Gespeichert in:
| Veröffentlicht in: | Journal of virology Jg. 85; H. 9; S. 4309 |
|---|---|
| Hauptverfasser: | , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.05.2011
|
| Schlagworte: | |
| ISSN: | 1098-5514, 1098-5514 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Marburgviruses are zoonotic pathogens that cause lethal hemorrhagic fever in humans and nonhuman primates. However, they do not cause lethal disease in immunocompetent mice unless they are adapted to this species. The adaptation process can therefore provide insight into the specific virus-host interactions that determine virulence. In primate cells, the Lake Victoria marburgvirus Musoke strain (MARV) VP40 matrix protein antagonizes alpha/beta interferon (IFN-α/β) and IFN-γ signaling by inhibiting the activation of the cellular tyrosine kinase Jak1. Here, VP40 from the Ravn strain (RAVV VP40)-from a distinct Marburg virus clade-is demonstrated to also inhibit IFN signaling in human cells. However, neither MARV nor RAVV VP40 effectively inhibited IFN-signaling in mouse cells, as assessed by assays of the antiviral effects of IFN-α/β and the IFN-α/β-induced phosphorylation of Jak1, STAT1, and STAT2. In contrast, the VP40 from a mouse-adapted RAVV (maRAVV) did inhibit IFN signaling. Effective Jak1 inhibition correlated with the species from which the cells were derived and did not depend upon whether Jak1 was of human or mouse origin. Of the seven amino acid changes that accumulated in VP40 during mouse adaptation, two (V57A and T165A) are sufficient to allow efficient IFN signaling antagonism by RAVV VP40 in mouse cells. The same two changes also confer efficient IFN antagonist function upon MARV VP40 in mouse cells. The mouse-adaptive changes did not affect the budding of RAVV VP40 in mouse cells, suggesting that this second major function of VP40 did not undergo adaptation. These data identify an apparent determinant of RAVV host range and virulence and define specific genetic determinants of this function. |
|---|---|
| AbstractList | Marburgviruses are zoonotic pathogens that cause lethal hemorrhagic fever in humans and nonhuman primates. However, they do not cause lethal disease in immunocompetent mice unless they are adapted to this species. The adaptation process can therefore provide insight into the specific virus-host interactions that determine virulence. In primate cells, the Lake Victoria marburgvirus Musoke strain (MARV) VP40 matrix protein antagonizes alpha/beta interferon (IFN-α/β) and IFN-γ signaling by inhibiting the activation of the cellular tyrosine kinase Jak1. Here, VP40 from the Ravn strain (RAVV VP40)-from a distinct Marburg virus clade-is demonstrated to also inhibit IFN signaling in human cells. However, neither MARV nor RAVV VP40 effectively inhibited IFN-signaling in mouse cells, as assessed by assays of the antiviral effects of IFN-α/β and the IFN-α/β-induced phosphorylation of Jak1, STAT1, and STAT2. In contrast, the VP40 from a mouse-adapted RAVV (maRAVV) did inhibit IFN signaling. Effective Jak1 inhibition correlated with the species from which the cells were derived and did not depend upon whether Jak1 was of human or mouse origin. Of the seven amino acid changes that accumulated in VP40 during mouse adaptation, two (V57A and T165A) are sufficient to allow efficient IFN signaling antagonism by RAVV VP40 in mouse cells. The same two changes also confer efficient IFN antagonist function upon MARV VP40 in mouse cells. The mouse-adaptive changes did not affect the budding of RAVV VP40 in mouse cells, suggesting that this second major function of VP40 did not undergo adaptation. These data identify an apparent determinant of RAVV host range and virulence and define specific genetic determinants of this function.Marburgviruses are zoonotic pathogens that cause lethal hemorrhagic fever in humans and nonhuman primates. However, they do not cause lethal disease in immunocompetent mice unless they are adapted to this species. The adaptation process can therefore provide insight into the specific virus-host interactions that determine virulence. In primate cells, the Lake Victoria marburgvirus Musoke strain (MARV) VP40 matrix protein antagonizes alpha/beta interferon (IFN-α/β) and IFN-γ signaling by inhibiting the activation of the cellular tyrosine kinase Jak1. Here, VP40 from the Ravn strain (RAVV VP40)-from a distinct Marburg virus clade-is demonstrated to also inhibit IFN signaling in human cells. However, neither MARV nor RAVV VP40 effectively inhibited IFN-signaling in mouse cells, as assessed by assays of the antiviral effects of IFN-α/β and the IFN-α/β-induced phosphorylation of Jak1, STAT1, and STAT2. In contrast, the VP40 from a mouse-adapted RAVV (maRAVV) did inhibit IFN signaling. Effective Jak1 inhibition correlated with the species from which the cells were derived and did not depend upon whether Jak1 was of human or mouse origin. Of the seven amino acid changes that accumulated in VP40 during mouse adaptation, two (V57A and T165A) are sufficient to allow efficient IFN signaling antagonism by RAVV VP40 in mouse cells. The same two changes also confer efficient IFN antagonist function upon MARV VP40 in mouse cells. The mouse-adaptive changes did not affect the budding of RAVV VP40 in mouse cells, suggesting that this second major function of VP40 did not undergo adaptation. These data identify an apparent determinant of RAVV host range and virulence and define specific genetic determinants of this function. Marburgviruses are zoonotic pathogens that cause lethal hemorrhagic fever in humans and nonhuman primates. However, they do not cause lethal disease in immunocompetent mice unless they are adapted to this species. The adaptation process can therefore provide insight into the specific virus-host interactions that determine virulence. In primate cells, the Lake Victoria marburgvirus Musoke strain (MARV) VP40 matrix protein antagonizes alpha/beta interferon (IFN-α/β) and IFN-γ signaling by inhibiting the activation of the cellular tyrosine kinase Jak1. Here, VP40 from the Ravn strain (RAVV VP40)-from a distinct Marburg virus clade-is demonstrated to also inhibit IFN signaling in human cells. However, neither MARV nor RAVV VP40 effectively inhibited IFN-signaling in mouse cells, as assessed by assays of the antiviral effects of IFN-α/β and the IFN-α/β-induced phosphorylation of Jak1, STAT1, and STAT2. In contrast, the VP40 from a mouse-adapted RAVV (maRAVV) did inhibit IFN signaling. Effective Jak1 inhibition correlated with the species from which the cells were derived and did not depend upon whether Jak1 was of human or mouse origin. Of the seven amino acid changes that accumulated in VP40 during mouse adaptation, two (V57A and T165A) are sufficient to allow efficient IFN signaling antagonism by RAVV VP40 in mouse cells. The same two changes also confer efficient IFN antagonist function upon MARV VP40 in mouse cells. The mouse-adaptive changes did not affect the budding of RAVV VP40 in mouse cells, suggesting that this second major function of VP40 did not undergo adaptation. These data identify an apparent determinant of RAVV host range and virulence and define specific genetic determinants of this function. |
| Author | Basler, Christopher F Valmas, Charalampos |
| Author_xml | – sequence: 1 givenname: Charalampos surname: Valmas fullname: Valmas, Charalampos organization: Department Microbiology, Box 1124, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA – sequence: 2 givenname: Christopher F surname: Basler fullname: Basler, Christopher F |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21325424$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkDtPwzAUhS0Eog_YmJE3phRfx3GSEVU8ioroAF2ja8eOjBKn2AkS_HoqKBLTOTr69A1nRo597w0hF8AWALy4ftyuFoxneZYAOyJTYGWRZBmI4399QmYxvjEGQkhxSiYcUp4JLqZk84RBjaGhHy6MkW43glH0Aza9d18mUucHE6wJvafRNR5b55v9SJHGndHOxOQnrdO0Q-9NOCMnFttozg85J693ty_Lh2T9fL9a3qwTLXIYEl0qrjVqlFwaATKT2mqrZF3WNWhtDdS5Aiyg4ByZkjqtcytQqlLlKaSWz8nVr3cX-vfRxKHqXNSmbdGbfoxVsRczlhfZnrw8kKPqTF3tguswfFZ_J_BviNFg1Q |
| CitedBy_id | crossref_primary_10_3389_fmicb_2024_1387628 crossref_primary_10_1007_s00203_025_04277_4 crossref_primary_10_1128_JVI_02069_14 crossref_primary_10_1016_j_antiviral_2012_01_011 crossref_primary_10_1371_journal_pone_0056659 crossref_primary_10_1016_j_antiviral_2025_106211 crossref_primary_10_3390_v4091477 crossref_primary_10_1038_s41392_024_01917_x crossref_primary_10_1007_s00281_017_0637_x crossref_primary_10_1016_j_coi_2015_06_003 crossref_primary_10_1073_pnas_1213559109 crossref_primary_10_1016_j_jmb_2016_05_008 crossref_primary_10_2174_0122113525341920241015041123 crossref_primary_10_1038_s41598_025_12917_4 crossref_primary_10_1016_j_virol_2016_11_015 crossref_primary_10_1016_j_micpath_2024_106892 crossref_primary_10_1128_JVI_01643_14 crossref_primary_10_1038_nrmicro3524 crossref_primary_10_1016_j_virol_2014_12_002 crossref_primary_10_1128_JVI_02670_15 crossref_primary_10_1128_mmbr_00001_23 crossref_primary_10_3390_v7102892 crossref_primary_10_1016_j_antiviral_2019_104703 crossref_primary_10_1093_infdis_jiv010 crossref_primary_10_1016_j_coi_2016_03_003 crossref_primary_10_3390_v8060178 crossref_primary_10_3390_v4101878 crossref_primary_10_1016_j_virol_2015_03_030 crossref_primary_10_1016_j_it_2015_01_004 crossref_primary_10_3390_v11020137 crossref_primary_10_3390_v17081082 crossref_primary_10_3390_v7102867 crossref_primary_10_3390_v3070982 crossref_primary_10_1016_j_coviro_2019_03_001 crossref_primary_10_1038_s41598_017_03318_3 crossref_primary_10_1146_annurev_virology_100114_054923 crossref_primary_10_1093_infdis_jiy457 crossref_primary_10_1016_j_antiviral_2018_12_006 crossref_primary_10_3389_fmicb_2022_1040093 crossref_primary_10_1016_j_virol_2015_07_010 crossref_primary_10_1093_infdis_jiv539 crossref_primary_10_12688_f1000research_17573_1 crossref_primary_10_1038_s41467_025_58305_4 crossref_primary_10_1172_JCI194586 crossref_primary_10_1080_07391102_2023_2300134 crossref_primary_10_3201_eid3012_240818 crossref_primary_10_1038_s41598_020_59976_3 crossref_primary_10_3390_v3081501 crossref_primary_10_3389_fimmu_2022_865797 crossref_primary_10_3390_vaccines7010022 crossref_primary_10_1016_j_antiviral_2018_08_012 crossref_primary_10_1186_s12985_019_1272_z crossref_primary_10_3390_v10100517 crossref_primary_10_1128_JVI_00833_17 crossref_primary_10_1128_JVI_02607_15 crossref_primary_10_1093_femsre_fuw010 crossref_primary_10_1128_JVI_00191_20 crossref_primary_10_3389_fimmu_2017_01202 crossref_primary_10_1111_1469_0691_12673 crossref_primary_10_1128_JVI_02331_15 crossref_primary_10_1080_17460913_2025_2501924 crossref_primary_10_1016_j_smim_2019_101300 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1128/JVI.02575-10 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1098-5514 |
| ExternalDocumentID | 21325424 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R01 AI059536 – fundername: NIAID NIH HHS grantid: AI057158 – fundername: NIAID NIH HHS grantid: U54 AI057158 – fundername: NIAID NIH HHS grantid: AI059536 |
| GroupedDBID | --- -~X .55 .GJ 0R~ 18M 29L 2WC 39C 3O- 4.4 41~ 53G 5GY 5RE 5VS 6TJ 85S AAYJJ ABPPZ ACGFO ACNCT ADBBV AENEX AFFNX AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CGR CS3 CUY CVF D0S DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 MVM N9A NPM O9- OHT OK1 P2P RHI RNS RPM RSF TR2 UPT VH1 W2D W8F WH7 WOQ X7M Y6R YQT ZGI ZXP ~02 ~KM 7X8 AAFWJ AAGFI AFPKN |
| ID | FETCH-LOGICAL-c471t-c9b2ccaca626e41656cfcfb6d9dd1ccfe1d7b1a81822a0b6c3d7f4a6b9b7313f2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 70 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000289618600023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1098-5514 |
| IngestDate | Sun Nov 09 13:59:06 EST 2025 Thu Apr 03 07:02:09 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c471t-c9b2ccaca626e41656cfcfb6d9dd1ccfe1d7b1a81822a0b6c3d7f4a6b9b7313f2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/3126248 |
| PMID | 21325424 |
| PQID | 862600785 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_862600785 pubmed_primary_21325424 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-05-01 |
| PublicationDateYYYYMMDD | 2011-05-01 |
| PublicationDate_xml | – month: 05 year: 2011 text: 2011-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of virology |
| PublicationTitleAlternate | J Virol |
| PublicationYear | 2011 |
| References | 15464838 - Virology. 2004 Oct 25;328(2):177-84 19091859 - J Virol. 2009 Mar;83(5):2327-37 15864272 - Nat Rev Immunol. 2005 May;5(5):375-86 11369881 - J Gen Virol. 2001 Jun;82(Pt 6):1365-73 7657660 - J Biol Chem. 1995 Sep 1;270(35):20775-80 17940954 - J Infect Dis. 2007 Nov 15;196 Suppl 2:S232-6 11027311 - Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12289-94 17712412 - PLoS One. 2007;2(8):e764 20071589 - J Virol. 2010 Mar;84(6):3004-15 16188985 - J Virol. 2005 Oct;79(20):12828-39 17301151 - J Virol. 2007 May;81(9):4895-9 11062045 - Virology. 2000 Nov 10;277(1):147-55 9889967 - Adv Exp Med Biol. 1998;452:143-9 15883164 - J Biol Chem. 2005 Jul 8;280(27):25849-53 19369350 - J Virol. 2009 Jul;83(13):6404-15 9590172 - Cell. 1998 May 1;93(3):373-83 17928350 - J Virol. 2007 Dec;81(24):13469-77 20084112 - PLoS Pathog. 2010 Jan;6(1):e1000721 14734183 - FEMS Immunol Med Microbiol. 2004 Jan 15;40(1):27-31 17940965 - J Infect Dis. 2007 Nov 15;196 Suppl 2:S305-12 17961252 - Virol J. 2007;4:108 12559917 - J Mol Biol. 2003 Feb 14;326(2):493-502 20032189 - J Virol. 2010 Mar;84(5):2294-303 8800792 - Arch Virol Suppl. 1996;11:101-14 15101709 - Leuk Lymphoma. 2004 Feb;45(2):257-64 1660837 - Gene. 1991 Dec 15;108(2):193-9 20504928 - J Virol. 2010 Aug;84(15):7847-56 16698997 - J Virol. 2006 Jun;80(11):5168-78 7537214 - EMBO J. 1995 Apr 3;14(7):1421-9 11095724 - Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13871-6 17005661 - J Virol. 2006 Dec;80(24):12070-8 12502864 - J Virol. 2003 Jan;77(2):1501-11 19889762 - J Virol. 2010 Jan;84(2):1169-75 9728532 - J Infect Dis. 1998 Sep;178(3):651-61 8232552 - Nature. 1993 Nov 11;366(6451):129-35 9448698 - Virology. 1998 Jan 5;240(1):138-46 19649327 - PLoS Pathog. 2009 Jul;5(7):e1000536 12388709 - J Virol. 2002 Nov;76(22):11476-83 16848640 - PLoS Pathog. 2006 Jul;2(7):e73 20081868 - Nat Struct Mol Biol. 2010 Feb;17(2):165-72 16698996 - J Virol. 2006 Jun;80(11):5156-67 10864502 - J Mol Biol. 2000 Jun 30;300(1):103-12 17009868 - PLoS Pathog. 2006 Sep;2(9):e99 |
| References_xml | – reference: 9889967 - Adv Exp Med Biol. 1998;452:143-9 – reference: 19889762 - J Virol. 2010 Jan;84(2):1169-75 – reference: 11027311 - Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12289-94 – reference: 15864272 - Nat Rev Immunol. 2005 May;5(5):375-86 – reference: 19369350 - J Virol. 2009 Jul;83(13):6404-15 – reference: 15101709 - Leuk Lymphoma. 2004 Feb;45(2):257-64 – reference: 8800792 - Arch Virol Suppl. 1996;11:101-14 – reference: 16848640 - PLoS Pathog. 2006 Jul;2(7):e73 – reference: 12388709 - J Virol. 2002 Nov;76(22):11476-83 – reference: 20084112 - PLoS Pathog. 2010 Jan;6(1):e1000721 – reference: 9590172 - Cell. 1998 May 1;93(3):373-83 – reference: 12502864 - J Virol. 2003 Jan;77(2):1501-11 – reference: 9728532 - J Infect Dis. 1998 Sep;178(3):651-61 – reference: 16698996 - J Virol. 2006 Jun;80(11):5156-67 – reference: 17712412 - PLoS One. 2007;2(8):e764 – reference: 20032189 - J Virol. 2010 Mar;84(5):2294-303 – reference: 17940954 - J Infect Dis. 2007 Nov 15;196 Suppl 2:S232-6 – reference: 9448698 - Virology. 1998 Jan 5;240(1):138-46 – reference: 15883164 - J Biol Chem. 2005 Jul 8;280(27):25849-53 – reference: 17961252 - Virol J. 2007;4:108 – reference: 20504928 - J Virol. 2010 Aug;84(15):7847-56 – reference: 19091859 - J Virol. 2009 Mar;83(5):2327-37 – reference: 17009868 - PLoS Pathog. 2006 Sep;2(9):e99 – reference: 11095724 - Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13871-6 – reference: 17928350 - J Virol. 2007 Dec;81(24):13469-77 – reference: 15464838 - Virology. 2004 Oct 25;328(2):177-84 – reference: 1660837 - Gene. 1991 Dec 15;108(2):193-9 – reference: 17301151 - J Virol. 2007 May;81(9):4895-9 – reference: 11062045 - Virology. 2000 Nov 10;277(1):147-55 – reference: 7537214 - EMBO J. 1995 Apr 3;14(7):1421-9 – reference: 10864502 - J Mol Biol. 2000 Jun 30;300(1):103-12 – reference: 17005661 - J Virol. 2006 Dec;80(24):12070-8 – reference: 19649327 - PLoS Pathog. 2009 Jul;5(7):e1000536 – reference: 8232552 - Nature. 1993 Nov 11;366(6451):129-35 – reference: 11369881 - J Gen Virol. 2001 Jun;82(Pt 6):1365-73 – reference: 12559917 - J Mol Biol. 2003 Feb 14;326(2):493-502 – reference: 17940965 - J Infect Dis. 2007 Nov 15;196 Suppl 2:S305-12 – reference: 20081868 - Nat Struct Mol Biol. 2010 Feb;17(2):165-72 – reference: 14734183 - FEMS Immunol Med Microbiol. 2004 Jan 15;40(1):27-31 – reference: 7657660 - J Biol Chem. 1995 Sep 1;270(35):20775-80 – reference: 16698997 - J Virol. 2006 Jun;80(11):5168-78 – reference: 16188985 - J Virol. 2005 Oct;79(20):12828-39 – reference: 20071589 - J Virol. 2010 Mar;84(6):3004-15 |
| SSID | ssj0014464 |
| Score | 2.3001595 |
| Snippet | Marburgviruses are zoonotic pathogens that cause lethal hemorrhagic fever in humans and nonhuman primates. However, they do not cause lethal disease in... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 4309 |
| SubjectTerms | Animals Cell Line Humans Interferon-alpha - antagonists & inhibitors Interferon-beta - antagonists & inhibitors Interferon-gamma - antagonists & inhibitors Janus Kinase 1 - metabolism Marburgvirus - pathogenicity Mice Phosphorylation Signal Transduction STAT1 Transcription Factor - metabolism STAT2 Transcription Factor - metabolism Viral Matrix Proteins - immunology Viral Matrix Proteins - metabolism |
| Title | Marburg virus VP40 antagonizes interferon signaling in a species-specific manner |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21325424 https://www.proquest.com/docview/862600785 |
| Volume | 85 |
| WOSCitedRecordID | wos000289618600023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7UKnjx_agv9uB1bbJ5dU8iYlGxJQctvZV9Sg8mNWkL-uudSVI9iQcvCYQEli-zO9_szH5DyCVw8igKpGE69hyD-IszIUPBhOYQigU2jF0lmf-UDAbd0UikTW1O2ZRVLtfEaqE2ucY98k7FvMGfRdfTd4ZNozC52nTQWCWtAJgMGnUy-kkiQKRTJZVRMhOJwbLunXc7j8OHK_D2Capw_s4tKx_T2_7n6HbIVkMu6U1tDbtkxWZ7ZKNuN_mxT9K-RAxf6WJSzEs6TEOPArDyFeb1py0pSkcUzhZ5RrGsQ-JJdXhIJcXzmBBSs-ruJpq-SWzZdUBeenfPt_es6ajANDihGdNCcfhlWsJwbYjCO9ppp2IjjPG1dtY3ifIlOHHOpadiHZjEhTJWQiWAsOOHZC3LM3tMKLwsuaec5ysRGgkXkZiga5SRkW98v03oEqkxWCymIWRm83k5_saqTY5qtMfTWlljzCE2jkIenvz98SnZrLd3sfbwjLQczFZ7Ttb1YjYpi4vKEuA6SPtf90q_Hg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Marburg+virus+VP40+antagonizes+interferon+signaling+in+a+species-specific+manner&rft.jtitle=Journal+of+virology&rft.au=Valmas%2C+Charalampos&rft.au=Basler%2C+Christopher+F&rft.date=2011-05-01&rft.eissn=1098-5514&rft.volume=85&rft.issue=9&rft.spage=4309&rft_id=info:doi/10.1128%2FJVI.02575-10&rft_id=info%3Apmid%2F21325424&rft_id=info%3Apmid%2F21325424&rft.externalDocID=21325424 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-5514&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-5514&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-5514&client=summon |